Close Menu

cell-free DNA

Researchers used bisulfite sequencing to identify methylation markers in order to trace circulating DNA fragments back to their tissue of origin. 

The new subsidiary will focus on expanding the company's liquid biopsy technology capabilities and growing European adoption of its platform.

The company also plans to submit its Panorama Microdeletion NIPT for US Food and Drug Administration clearance.

In PNAS this week: tumor DNA in cerebrospinal fluid, genetic factors influencing ability to sweat in humans, and more.

The study paves the way for a clinical trial testing the use of CSF tumor DNA as a biomarker for brain and spinal cord tumors.

The goal is to detect both clonal and subclonal variations and to demonstrate how Natera's technology can help improve cancer patient care and treatment outcomes.

A proof-of-principle study suggests blood and saliva may contain markers for finding and following head and neck squamous cell carcinomas.

The company plans to expand its CLIA testing and complete a major study in theUS, as it moves forward to open a joint venture inChinathat will support further commercial expansion and clinical utility research.

Patent law experts said the ruling provides further clarity over what is and is not patentable within the broader molecular diagnostics field. 

The so-called '540 patent has been the focal point of a series of lawsuits between Sequenom and other NIPT firms since 2011. 


A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.